SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.87-2.3%Dec 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Metcalf who wrote (9423)11/6/2003 2:41:01 AM
From: Miljenko Zuanic  Read Replies (2) of 52153
 
After reading JAMA article my layman concerns are:
1. Severely compromised baseline placebo and drug groups characteristic (LDL and HDL baseline level and few other measurements). I will say that this was *intentionally* done by INVESTIGATORS, the same ones that asked for JAMA embargo. From what is known ApoA-IM does have effects on pts with LOW HDL level.
2. Second observation is NO CHANGE in coronary luminal diameter and lumen volume. The two measurements that may bring clinical benefit to plagued arteries in CAD.
3. Third is that benefit was only for severe part of the plagued artery segment.
4. Forth, one stroke case in 15 mg group.
5. No dose response relation, Opposite?
6. ….

Results are far less positive than today market reaction, imo.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News